Mitochondrial dysfunction associated with glucocerebrosidase deficiency

Neurobiology of Disease

Volumn 90, Issue , 2016, Pages 43-50

  Gegg, Matthew E ^a   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autophagy; Gaucher disease; Glucocerebrosidase; Lysosome; Mitochondria; Mitophagy; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; HYDROLASE; LYSOSOME ENZYME;

ARTICLE; AUTOPHAGY; CELL ORGANELLE; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME DEFICIENCY; GAUCHER DISEASE; GENETIC RISK; GLUCOCEREBROSIDASE DEFICIENCY; HUMAN; LEWY BODY; LYSOSOME; MACROMOLECULE; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; METABOLISM;

ANIMALS; GAUCHER DISEASE; HUMANS; MITOCHONDRIA;

EID: 84945572141     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.09.006     Document Type: Article

References (92)

1. Alcalay R.N., Caccappolo E., Mejia-Santana H., Tang M.-X., Rosado L., Orbe Reilly M., Ruiz D., Ross B., Verbitsky M., Kisselev S., Louis E., Comella C., Colcher A., Jennings D., Nance M., Bressman S., Scott W.K., Tanner C., Mickel S., Andrews H., Waters C., Fahn S., Cote L., Frucht S., Ford B., Rezak M., Novak K., Friedman J.H., Pfeiffer R., Marsh L., Hiner B., Siderowf A., Payami H., Molho E., Factor S., Ottman R., Clark L.N., Marder K. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012, 78:1434-1440. 10.1212/WNL.0b013e318253d54b.
2. Alvarez-Erviti L., Rodriguez-Oroz M.C., Cooper J.M., Caballero C., Ferrer I., Obeso J.A., Schapira A.H.V. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch. Neurol. 2010, 67:1464-1472. 10.1001/archneurol.2010.198.
3. Bae E.-J., Yang N.-Y., Song M., Lee C.S., Lee J.S., Jung B.C., Lee H.-J., Kim S., Masliah E., Sardi S.P., Lee S.-J. Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein. Nat. Commun. 2014, 5:4755. 10.1038/ncomms5755.
4. Beavan M., McNeill A., Proukakis C., Hughes D.A., Mehta A., Schapira A.H.V. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol. 2015, 72:201-208. 10.1001/jamaneurol.2014.2950.
5. Bembi B., Zambito Marsala S., Sidransky E., Ciana G., Carrozzi M., Zorzon M., Martini C., Gioulis M., Pittis M.G., Capus L. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003, 61:99-101.
6. Bolaños J.P., Heales S.J., Land J.M., Clark J.B. Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture. J. Neurochem. 1995, 64:1965-1972.
7. Bolaños J.P., Heales S.J., Peuchen S., Barker J.E., Land J.M., Clark J.B. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic. Biol. Med. 1996, 21:995-1001.
8. Bolaños J.P., Peuchen S., Heales S.J., Land J.M., Clark J.B. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J. Neurochem. 1994, 63:910-916.
9. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C.J., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299:256-259. 10.1126/science.1077209.
10. Brockmann K., Srulijes K., Hauser A.K., Schulte C., Csoti I., Gasser T., Berg D. GBA-associated PD presents with nonmotor characteristics. Neurology 2011, 77:276-280. 10.1212/WNL.0b013e318225ab77.
11. Burchell V.S., Gandhi S., Deas E., Wood N.W., Abramov A.Y., Plun-Favreau H. Targeting mitochondrial dysfunction in neurodegenerative disease: part I. Expert Opin. Ther. Targets 2010, 14:369-385. 10.1517/14728221003652489.
12. Chu C.T., Ji J., Dagda R.K., Jiang J.F., Tyurina Y.Y., Kapralov A.A., Tyurin V.A., Yanamala N., Shrivastava I.H., Mohammadyani D., Qiang Wang K.Z., Zhu J., Klein-Seetharaman J., Balasubramanian K., Amoscato A.A., Borisenko G., Huang Z., Gusdon A.M., Cheikhi A., Steer E.K., Wang R., Baty C., Watkins S., Bahar I., Bayir H., Kagan V.E. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells. Nat. Cell Biol. 2013, 15:1197-1205. 10.1038/ncb2837.
13. Cleeter M.W.J., Chau K.-Y., Gluck C., Mehta A., Hughes D.A., Duchen M., Wood N.W., Hardy J., Mark Cooper J., Schapira A.H. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem. Int. 2013, 62:1-7. 10.1016/j.neuint.2012.10.010.
14. Cleeter M.W., Cooper J.M., Darley-Usmar V.M., Moncada S., Schapira A.H. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett. 1994, 345:50-54.
15. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295. 10.1126/science.1101738.
16. Cullen V., Sardi S.P., Ng J., Xu Y.-H., Sun Y., Tomlinson J.J., Kolodziej P., Kahn I., Saftig P., Woulfe J., Rochet J.-C., Glicksman M.A., Cheng S.H., Grabowski G.A., Shihabuddin L.S., Schlossmacher M.G. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann. Neurol. 2011, 69:940-953. 10.1002/ana.22400.
17. De la Mata M., Cotán D., Oropesa-Ávila M., Garrido-Maraver J., Cordero M.D., Villanueva Paz M., Delgado Pavón A., Alcocer-Gómez E., de Lavera I., Ybot-González P., Paula Zaderenko A., Ortiz Mellet C., Fernández J.M.G., Sánchez-Alcázar J.A. Pharmacological chaperones and coenzyme q10 treatment improves mutant β-grrlucocerebrosidase activity and mitochondrial function in neuronopathic forms of Gaucher disease. Sci. Rep. 2015, 5:10903. 10.1038/srep10903.
18. Dehay B., Bové J., Rodríguez-Muela N., Perier C., Recasens A., Boya P., Vila M. Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 2010, 30:12535-12544. 10.1523/JNEUROSCI.1920-10.2010.
19. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283:9089-9100. 10.1074/jbc.M710012200.
20. Ding W.-X., Ni H.-M., Li M., Liao Y., Chen X., Stolz D.B., Dorn G.W., Yin X.-M. Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. J. Biol. Chem. 2010, 285:27879-27890. 10.1074/jbc.M110.119537.
21. Dryanovski D.I., Guzman J.N., Xie Z., Galteri D.J., Volpicelli-Daley L.A., Lee V.M.-Y., Miller R.J., Schumacker P.T., Surmeier D.J. Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci. 2013, 33:10154-10164. 10.1523/JNEUROSCI.5311-12.2013.
22. Enquist I.B., Lo Bianco C., Ooka A., Nilsson E., Månsson J.-E., Ehinger M., Richter J., Brady R.O., Kirik D., Karlsson S. Murine models of acute neuronopathic Gaucher disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17483-17488. 10.1073/pnas.0708086104.
23. Farfel-Becker T., Vitner E.B., Kelly S.L., Bame J.R., Duan J., Shinder V., Merrill A.H., Dobrenis K., Futerman A.H. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum. Mol. Genet. 2014, 23:843-854. 10.1093/hmg/ddt468.
24. Farfel-Becker T., Vitner E.B., Pressey S.N.R., Eilam R., Cooper J.D., Futerman A.H. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum. Mol. Genet. 2011, 20:1375-1386. 10.1093/hmg/ddr019.
25. Fishbein I., Kuo Y.-M., Giasson B.I., Nussbaum R.L. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain 2014, 137:3235-3247. 10.1093/brain/awu291.
26. Gautier C.A., Kitada T., Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11364-11369. 10.1073/pnas.0802076105.
27. Gegg M.E., Burke D., Heales S.J.R., Cooper J.M., Hardy J., Wood N.W., Schapira A.H.V. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol. 2012, 72:455-463. 10.1002/ana.23614.
28. Gegg M.E., Clark J.B., Heales S.J.R. Co-culture of neurones with glutathione deficient astrocytes leads to increased neuronal susceptibility to nitric oxide and increased glutamate-cysteine ligase activity. Brain Res. 2005, 1036:1-6. 10.1016/j.brainres.2004.11.064.
29. Gegg M.E., Cooper J.M., Chau K.-Y., Rojo M., Schapira A.H.V., Taanman J.-W. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum. Mol. Genet. 2010, 19:4861-4870. 10.1093/hmg/ddq419.
30. Gegg M.E., Cooper J.M., Schapira A.H.V., Taanman J.-W. Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One 2009, 4:e4756. 10.1371/journal.pone.0004756.
31. Gegg M.E., Sweet L., Wang B.H., Shihabuddin L.S., Sardi S.P., Schapira A.H.V. No evidence for substrate accumulation in Parkinson brains with GBA mutations. Mov. Disord. 2015, 30:1085-1089. 10.1002/mds.26278.
32. Geisler S., Holmström K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131. 10.1038/ncb2012.
33. Grabowski G.A. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008, 372:1263-1271. 10.1016/S0140-6736(08)61522-6.
34. Grace M.E., Ashton-Prolla P., Pastores G.M., Soni A., Desnick R.J. Non-pseudogene-derived complex acid beta-glucosidase mutations causing mild type 1 and severe type 2 gaucher disease. J. Clin. Invest. 1999, 103:817-823. 10.1172/JCI5168.
35. Guo J.L., Lee V.M.Y. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 2014, 20:130-138. 10.1038/nm.3457.
36. Hargreaves I.P. Coenzyme Q10 as a therapy for mitochondrial disease. Int. J. Biochem. Cell Biol. 2014, 49:105-111. 10.1016/j.biocel.2014.01.020.
37. Hruska K.S., LaMarca M.E., Scott C.R., Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 2008, 29:567-583. 10.1002/humu.20676.
38. Kazlauskaite A., Kondapalli C., Gourlay R., Campbell D.G., Ritorto M.S., Hofmann K., Alessi D.R., Knebel A., Trost M., Muqit M.M.K. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem. J. 2014, 460:127-139. 10.1042/BJ20140334.
39. Kim I., Rodriguez-Enriquez S., Lemasters J.J. Selective degradation of mitochondria by mitophagy. Arch. Biochem. Biophys. 2007, 462:245-253. 10.1016/j.abb.2007.03.034.
40. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608. 10.1038/33416.
41. Koyano F., Okatsu K., Kosako H., Tamura Y., Go E., Kimura M., Kimura Y., Tsuchiya H., Yoshihara H., Hirokawa T., Endo T., Fon E.A., Trempe J.-F., Saeki Y., Tanaka K., Matsuda N. Ubiquitin is phosphorylated by PINK1 to activate parkin. Nature 2014, 10.1038/nature13392.
42. Lee J.-Y., Nagano Y., Taylor J.P., Lim K.L., Yao T.-P. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. J. Cell Biol. 2010, 189:671-679. 10.1083/jcb.201001039.
43. Liou B., Kazimierczuk A., Zhang M., Scott C.R., Hegde R.S., Grabowski G.A. Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations. J. Biol. Chem. 2006, 281:4242-4253. 10.1074/jbc.M511110200.
44. Liu L., Feng D., Chen G., Chen M., Zheng Q., Song P., Ma Q., Zhu C., Wang R., Qi W., Huang L., Xue P., Li B., Wang X., Jin H., Wang J., Yang F., Liu P., Zhu Y., Sui S., Chen Q. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells. Nat. Cell Biol. 2012, 14:177-185. 10.1038/ncb2422.
45. Lloyd-Evans E., Pelled D., Riebeling C., Bodennec J., de- Morgan A., Waller H., Schiffmann R., Futerman A.H. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J. Biol. Chem. 2003, 278:23594-23599. 10.1074/jbc.M300212200.
46. Luk K.C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J.Q., Lee V.M.-Y. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953. 10.1126/science.1227157.
47. Luth E.S., Stavrovskaya I.G., Bartels T., Kristal B.S., Selkoe D.J. Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2 + -induced mitochondrial dysfunction. J. Biol. Chem. 2014, 289:21490-21507. 10.1074/jbc.M113.545749.
48. Manning-Boğ A.B., Schüle B., Langston J.W. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 2009, 30:1127-1132. 10.1016/j.neuro.2009.06.009.
49. Matalonga L., Arias A., Coll M.J., Garcia-Villoria J., Gort L., Ribes A. Treatment effect of coenzyme Q(10) and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease. J. Inherit. Metab. Dis. 2014, 37:439-446. 10.1007/s10545-013-9668-1.
50. Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C.A., Sou Y.-S., Saiki S., Kawajiri S., Sato F., Kimura M., Komatsu M., Hattori N., Tanaka K. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 2010, 189:211-221. 10.1083/jcb.200910140.
51. Mazzulli J.R., Xu Y.-H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., Sidransky E., Grabowski G.A., Krainc D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52. 10.1016/j.cell.2011.06.001.
52. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075. 10.1038/nature06639.
53. Mu T.-W., Ong D.S.T., Wang Y.-J., Balch W.E., Yates J.R., Segatori L., Kelly J.W. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008, 134:769-781. 10.1016/j.cell.2008.06.037.
54. Murphy K.E., Gysbers A.M., Abbott S.K., Tayebi N., Kim W.S., Sidransky E., Cooper A., Garner B., Halliday G.M. Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain 2014, 137:834-848. 10.1093/brain/awt367.
55. Nalls M.A., Duran R., Lopez G., Kurzawa-Akanbi M., McKeith I.G., Chinnery P.F., Morris C.M., Theuns J., Crosiers D., Cras P., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Mann D.M.A., Snowden J., Pickering-Brown S., Halliwell N., Davidson Y., Gibbons L., Harris J., Sheerin U.-M., Bras J., Hardy J., Clark L., Marder K., Honig L.S., Berg D., Maetzler W., Brockmann K., Gasser T., Novellino F., Quattrone A., Annesi G., De Marco E.V., Rogaeva E., Masellis M., Black S.E., Bilbao J.M., Foroud T., Ghetti B., Nichols W.C., Pankratz N., Halliday G., Lesage S., Klebe S., Durr A., Duyckaerts C., Brice A., Giasson B.I., Trojanowski J.Q., Hurtig H.I., Tayebi N., Landazabal C., Knight M.A., Keller M., Singleton A.B., Wolfsberg T.G., Sidransky E. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013, 70:727-735. 10.1001/jamaneurol.2013.1925.
56. Narendra D.P., Jin S.M., Tanaka A., Suen D.-F., Gautier C.A., Shen J., Cookson M.R., Youle R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010, 8:e1000298. 10.1371/journal.pbio.1000298.
57. Narendra D., Tanaka A., Suen D.-F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008, 183:795-803. 10.1083/jcb.200809125.
58. Neudorfer O., Giladi N., Elstein D., Abrahamov A., Turezkite T., Aghai E., Reches A., Bembi B., Zimran A. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM Mon. J. Assoc. Physicians 1996, 89:691-694.
59. Neumann J., Bras J., Deas E., O'Sullivan S.S., Parkkinen L., Lachmann R.H., Li A., Holton J., Guerreiro R., Paudel R., Segarane B., Singleton A., Lees A., Hardy J., Houlden H., Revesz T., Wood N.W. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain J. Neurol. 2009, 132:1783-1794. 10.1093/brain/awp044.
60. Nilsson O., Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease 1982.
61. Nilsson O., Grabowski G.A., Ludman M.D., Desnick R.J., Svennerholm L. Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. Clin. Genet. 1985, 27:443-450.
62. Noelker C., Lu L., Höllerhage M., Vulinovic F., Sturn A., Roscher R., Höglinger G.U., Hirsch E.C., Oertel W.H., Alvarez-Fischer D., Hartmann A. Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. J. Neurol. Sci. 2015, 356:129-136. 10.1016/j.jns.2015.06.030.
63. Offman M.N., Krol M., Silman I., Sussman J.L., Futerman A.H. Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S. J. Biol. Chem. 2010, 285:42105-42114. 10.1074/jbc.M110.172098.
64. Orvisky E., Park J.K., LaMarca M.E., Ginns E.I., Martin B.M., Tayebi N., Sidransky E. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol. Genet. Metab. 2002, 76:262-270. 10.1016/S1096-7192(02)00117-8.
65. Osellame L.D., Rahim A.A., Hargreaves I.P., Gegg M.E., Richard-Londt A., Brandner S., Waddington S.N., Schapira A.H.V., Duchen M.R. Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab. 2013, 17:941-953. 10.1016/j.cmet.2013.04.014.
66. Parkkinen L., Neumann J., O'Sullivan S.S., Holton J.L., Revesz T., Hardy J., Lees A.J. Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Mol. Genet. Metab. 2011, 103:410-412. 10.1016/j.ymgme.2011.04.015.
67. Parzych K.R., Klionsky D.J. An overview of autophagy: morphology, mechanism, and regulation. Antioxid. Redox Signal. 2014, 20:460-473. 10.1089/ars.2013.5371.
68. Pelled D., Trajkovic-Bodennec S., Lloyd-Evans E., Sidransky E., Schiffmann R., Futerman A.H. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol. Dis. 2005, 18:83-88. 10.1016/j.nbd.2004.09.004.
69. Reczek D., Schwake M., Schröder J., Hughes H., Blanz J., Jin X., Brondyk W., Van Patten S., Edmunds T., Saftig P. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 2007, 131:770-783. 10.1016/j.cell.2007.10.018.
70. Ron I., Horowitz M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 2005, 14:2387-2398. 10.1093/hmg/ddi240.
71. Salvioli R., Tatti M., Scarpa S., Moavero S.M., Ciaffoni F., Felicetti F., Kaneski C.R., Brady R.O., Vaccaro A.M. The N370S (Asn370- > Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C. Biochem. J. 2005, 390:95-103. 10.1042/BJ20050325.
72. Sardi S.P., Clarke J., Kinnecom C., Tamsett T.J., Li L., Stanek L.M., Passini M.A., Grabowski G.A., Schlossmacher M.G., Sidman R.L., Cheng S.H., Shihabuddin L.S. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12101-12106. 10.1073/pnas.1108197108.
73. Sardi S.P., Clarke J., Viel C., Chan M., Tamsett T.J., Treleaven C.M., Bu J., Sweet L., Passini M.A., Dodge J.C., Yu W.H., Sidman R.L., Cheng S.H., Shihabuddin L.S. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3537-3542. 10.1073/pnas.1220464110.
74. Sarraf S.A., Raman M., Guarani-Pereira V., Sowa M.E., Huttlin E.L., Gygi S.P., Harper J.W. Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 2013, 496:372-376. 10.1038/nature12043.
75. Schapira A.H.V., Gegg M. Mitochondrial contribution to Parkinson's disease pathogenesis. Park. Dis. 2011, 2011:159160. 10.4061/2011/159160.
76. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 2011, 26:1049-1055. 10.1002/mds.23732.
77. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
78. Schöndorf D.C., Aureli M., McAllister F.E., Hindley C.J., Mayer F., Schmid B., Sardi S.P., Valsecchi M., Hoffmann S., Schwarz L.K., Hedrich U., Berg D., Shihabuddin L.S., Hu J., Pruszak J., Gygi S.P., Sonnino S., Gasser T., Deleidi M. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 2014, 5:4028. 10.1038/ncomms5028.
79. Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G., Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.-M., Clark L.N., Condroyer C., De Marco E.V., Dürr A., Eblan M.J., Fahn S., Farrer M.J., Fung H.-C., Gan-Or Z., Gasser T., Gershoni-Baruch R., Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E., Lee-Chen G.-J., Lesage S., Marder K., Mata I.F., Mirelman A., Mitsui J., Mizuta I., Nicoletti G., Oliveira C., Ottman R., Orr-Urtreger A., Pereira L.V., Quattrone A., Rogaeva E., Rolfs A., Rosenbaum H., Rozenberg R., Samii A., Samaddar T., Schulte C., Sharma M., Singleton A., Spitz M., Tan E.-K., Tayebi N., Toda T., Troiano A.R., Tsuji S., Wittstock M., Wolfsberg T.G., Wu Y.-R., Zabetian C.P., Zhao Y., Ziegler S.G. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009, 361:1651-1661. 10.1056/NEJMoa0901281.
80. Stewart V.C., Sharpe M.A., Clark J.B., Heales S.J. Astrocyte-derived nitric oxide causes both reversible and irreversible damage to the neuronal mitochondrial respiratory chain. J. Neurochem. 2000, 75:694-700.
81. Sun Y., Liou B., Ran H., Skelton M.R., Williams M.T., Vorhees C.V., Kitatani K., Hannun Y.A., Witte D.P., Xu Y.-H., Grabowski G.A. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum. Mol. Genet. 2010, 19:1088-1097. 10.1093/hmg/ddp580.
82. Sun Y., Zhang W., Xu Y.-H., Quinn B., Dasgupta N., Liou B., Setchell K.D.R., Grabowski G.A. Substrate compositional variation with tissue/region and Gba1 mutations in mouse models-implications for Gaucher disease. PLoS One 2013, 8:e57560. 10.1371/journal.pone.0057560.
83. Tayebi N., Callahan M., Madike V., Stubblefield B.K., Orvisky E., Krasnewich D., Fillano J.J., Sidransky E. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab. 2001, 73:313-321. 10.1006/mgme.2001.3201.
84. Tolkovsky A.M., Xue L., Fletcher G.C., Borutaite V. Mitochondrial disappearance from cells: a clue to the role of autophagy in programmed cell death and disease?. Biochimie 2002, 84:233-240.
85. Twig G., Elorza A., Molina A.J.A., Mohamed H., Wikstrom J.D., Walzer G., Stiles L., Haigh S.E., Katz S., Las G., Alroy J., Wu M., Py B.F., Yuan J., Deeney J.T., Corkey B.E., Shirihai O.S. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 2008, 27:433-446. 10.1038/sj.emboj.7601963.
86. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M.K., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., González-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160. 10.1126/science.1096284.
87. Van Echten-Deckert G., Herget T. Sphingolipid metabolism in neural cells. Biochim. Biophys. Acta 2006, 1758:1978-1994. 10.1016/j.bbamem.2006.06.009.
88. Vitner E.B., Salomon R., Farfel-Becker T., Meshcheriakova A., Ali M., Klein A.D., Platt F.M., Cox T.M., Futerman A.H. RIPK3 as a potential therapeutic target for Gaucher's disease. Nat. Med. 2014, 20:204-208. 10.1038/nm.3449.
89. Vives-Bauza C., Zhou C., Huang Y., Cui M., de Vries R.L.A., Kim J., May J., Tocilescu M.A., Liu W., Ko H.S., Magrané J., Moore D.J., Dawson V.L., Grailhe R., Dawson T.M., Li C., Tieu K., Przedborski S. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:378-383. 10.1073/pnas.0911187107.
90. Wong K., Sidransky E., Verma A., Mixon T., Sandberg G.D., Wakefield L.K., Morrison A., Lwin A., Colegial C., Allman J.M., Schiffmann R. Neuropathology provides clues to the pathophysiology of gaucher disease. Mol. Genet. Metab. 2004, 82:192-207. 10.1016/j.ymgme.2004.04.011.
91. Xu Y.-H., Xu K., Sun Y., Liou B., Quinn B., Li R.-H., Xue L., Zhang W., Setchell K.D.R., Witte D., Grabowski G.A. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum. Mol. Genet. 2014, 10.1093/hmg/ddu105.
92. Yap T.L., Gruschus J.M., Velayati A., Westbroek W., Goldin E., Moaven N., Sidransky E., Lee J.C. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 2011, 286:28080-28088. 10.1074/jbc.M111.237859.